Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer

Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy. HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore...

Full description

Bibliographic Details
Main Authors: Elizabeth K. Lee, Zhenying Tan-Wasielewski, Ursula A. Matulonis, Michael J. Birrer, Alexi A. Wright, Neil Horowitz, Panagiotis A. Konstantinopoulos, Jennifer Curtis, Joyce F. Liu
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:Gynecologic Oncology Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2352578919300724

Internet

http://www.sciencedirect.com/science/article/pii/S2352578919300724

Similar Items